Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
CardioVascular and Interventional Radiology
Published in: CardioVascular and Interventional Radiology 7/2019

01-07-2019 | Kidney Cancer | Clinical Investigation

Percutaneous Cryoablation of Stage T1b Renal Cell Carcinoma: Safety, Technical Results, and Clinical Outcomes

Published in: CardioVascular and Interventional Radiology | Issue 7/2019

Login to get access

Abstract

Purpose

The use of percutaneous cryoablation for T1b (4.1–7.0 cm) renal cell carcinoma, has not yet been widely adopted. The purpose of this study was to describe our experience in the cryoablation of stage T1b tumors with an emphasis on safety, technical results, and clinical outcomes.

Materials and Methods

A retrospective review of hospital records identified 37 patients who underwent cryoablation for T1b lesions from 2008 to 2018. Patient demographics, comorbidities, tumor characteristics, technical parameters, and outcomes were recorded and analyzed. Recurrence-free, overall, and cancer-specific survival rates were estimated using the Kaplan–Meier method.

Results

Thirty-seven patients (22 males, 15 females; mean age 66.5 ± 11.3) with 37 T1b tumors (mean diameter 47.3 ± 6.3 mm) were included. A median of 3 probes were used (range: 1–7). Angio-embolization was used in 3/37 (8.1%) and 2/37 patients (5.4%) required hydrodissection. The mean number of total cryoablation procedures for each patient was 1.5 (median 1; range: 1–4). Technical success was achieved in 88.2% of patients. Recurrence-free survival was 96.5%, 86.1%, and 62.6% at 1, 2, and 3 years respectively. Cancer-specific survival was 100% at 1, 2, and 3 years respectively. Overall survival was 96.7%, 91.8%, and 77.6% at 1, 2, and 3 years respectively. Complications classified as CIRSE grade 2 or higher occurred in 6/37 (16.2%) patients.

Conclusion

T1b cryoablation is associated with high rates of technical success, excellent cancer-specific survival, and an acceptable safety profile.

Level of Evidence

Level 4, Case Series.
Literature
1.
Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–30.CrossRefPubMed
2.
Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011;59(1):135–41.CrossRef
3.
4.
Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331–4.CrossRef
5.
6.
7.
Campbell S, Uzzo RG, Allaf ME, Bass EB, Cadeddu JA, Chang A, et al. Renal mass and localized renal cancer: AUA guideline. J Urol. 2017;198(3):520–9.CrossRef
8.
Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol. 2015;67(2):252–9.CrossRef
9.
Takaki H, Yamakado K, Soga N, Arima K, Nakatsuka A, Kashima M, et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. Jpn J Radiol. 2010;28(6):460–8.CrossRefPubMed
10.
Yang Y, Chen S, Chen F, Zhu K, Deng Q, Luo L, et al. Outcome of radiofrequency ablation over partial nephrectomy for small renal mass (< 4 cm): a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(11):20670.PubMedPubMedCentral
11.
Dandrea D, Shariat SF, Klatte T. Update on ablative therapies of renal tumors. Curr Opin Urol. 2016;26(5):410–6.CrossRef
12.
Moreland AJ, Ziemlewicz TJ, Best SL, Hinshaw JL, Lubner MG, Alexander ML, et al. High-powered microwave ablation of t1a renal cell carcinoma: safety and initial clinical evaluation. J Endourol. 2014;28(9):1046–52.CrossRefPubMed
13.
Tanagho YS, Roytman TM, Bhayani SB, Kim EH, Benway BM, Gardner MW, et al. Laparoscopic cryoablation of renal masses: single-center long-term experience. Urology. 2012;80(2):307–14.CrossRefPubMed
14.
Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol. 2005;185(1):64–71.CrossRefPubMed
15.
Best SL, Park SK, Yaacoub RF, Olweny EO, Tan YK, Trimmer C, et al. Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters. J Urol. 2012;187(4):1183–9.CrossRefPubMed
16.
Schmit GD, Thompson RH, Kurup AN, Weisbrod AJ, Carter RE, Callstrom MR, et al. Percutaneous cryoablation of solitary sporadic renal cell carcinomas. BJU Int. 2012;110(11b):E526–31.CrossRefPubMed
17.
Schmit GD, Atwell TD, Callstrom MR, Farrell MA, Leibovich BC, Patterson DE, et al. Percutaneous cryoablation of renal masses ≥ 3 cm: efficacy and safety in treatment of 108 patients. J Endourol. 2010;24(8):1255–62.CrossRefPubMed
18.
Atwell TD, Vlaminck JJ, Boorjian SA, Kurup AN, Callstrom MR, Weisbrod AJ, et al. Percutaneous cryoablation of stage T1b renal cell carcinoma: technique considerations, safety, and local tumor control. J Vasc Interv Radiol. 2015;26(6):792–9.CrossRefPubMed
19.
Hasegawa T, Yamanaka T, Gobara H, Miyazaki M, Takaki H, Sato Y, et al. Radiofrequency ablation versus cryoablation for T1b renal cell carcinoma: a multi-center study. Jpn J Radiol. 2018;36(9):551–8.CrossRefPubMed
20.
Atwell TD, Carter RE, Schmit GD, Carr CM, Boorjian SA, Curry TB, et al. Complications following 573 percutaneous renal radiofrequency and cryoablation procedures. J Vasc Interv Radiol. 2012;23(1):48–54.CrossRef
21.
Hebbadj S, Cazzato RL, Garnon J, Shaygi B, Buy X, Tsoumakidou G, et al. Safety considerations and local tumor control following percutaneous image-guided cryoablation of T1b renal tumors. Cardiovac Intervent Radiol. 2018;41(3):449–58.CrossRef
22.
Kutikov A, Uzzo RG. The RENAL nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol. 2009;182(3):844–53.CrossRef
23.
Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol. 2009;56(5):786–93.CrossRefPubMed
24.
Venkatesan AM, Kundu S, Sacks D, Wallace MJ, Wojak JC, Rose SC, et al. Practice guideline for adult antibiotic prophylaxis during vascular and interventional radiology procedures. J Vasc Interv Radiol. 2010;21(11):1611–30.CrossRefPubMed
25.
Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2012;23(6):727–36.CrossRef
26.
Chung MS, Maxwell AW, Wang LJ, Mayo-Smith WW, Dupuy DE. Should renal mass biopsy be performed prior to or concomitantly with thermal ablation? J Vasc Interv Radiol. 2018;29(9):1240–4.CrossRef
27.
Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Interv Radiol. 2017;40(8):1141–6.CrossRef
28.
Higgins LJ, Hong K. Renal ablation techniques: state of the art. AJR Am J Roentgenol. 2015;205(4):735–41.CrossRefPubMed
29.
Patel N, King AJ, Breen DJ. Percutaneous image-guided cryoablation of small renal masses. Abdom Radiol (NY). 2016;41(4):754–66.CrossRef
30.
Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011;258(2):351–69.CrossRefPubMed
31.
Maxwell AW, Baird GL, Iannuccilli JD, Mayo-Smith WW, Dupuy DE. Renal cell carcinoma: comparison of RENAL nephrometry and PADUA scores with maximum tumor diameter for prediction of local recurrence after thermal ablation. Radiology. 2017;283(2):590–7.CrossRefPubMed
32.
Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, et al. Management of renal masses and localized renal cancer: systematic review and meta-analysis. J Urol. 2016;196(4):989–99.CrossRefPubMedPubMedCentral
33.
Taylor BL, Stavropoulos SW, Guzzo TJ. Ablative therapy for small renal masses. Urol Clin North Am. 2017;44(2):223–31.CrossRefPubMed
34.
Schmit GD, Schenck LA, Thompson RH, Boorjian SA, Kurup AN, Weisbrod AJ, et al. Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology. 2014;272(3):903–10.CrossRefPubMed
Metadata
Title
Percutaneous Cryoablation of Stage T1b Renal Cell Carcinoma: Safety, Technical Results, and Clinical Outcomes
Publication date
01-07-2019
Published in
CardioVascular and Interventional Radiology / Issue 7/2019
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-019-02226-5

Other articles of this Issue 7/2019

CardioVascular and Interventional Radiology 7/2019 Go to the issue

Laboratory Investigation

Robotically Assisted Sonic Therapy (RAST) for Noninvasive Hepatic Ablation in a Porcine Model: Mitigation of Body Wall Damage with a Modified Pulse Sequence

Review

Current Status of Endovascular Preservation of the Internal Iliac Artery with Iliac Branch Devices (IBD)

Case Report

Monomelic Ischemic Neuropathy of the Tibial and Peroneal Nerve After Onyx Embolization of Vasa Nervorum Supplying a Surgically Excluded Popliteal Artery Aneurysm

Clinical Investigation

Local Ultrasound-Facilitated Thrombolysis in High-Risk Pulmonary Embolism: First Dutch Experience

Clinical Investigation

Onyx Embolization for Occlusion of the Proximal Internal Iliac Artery During EVAR in Patients with Unsuitable Landing Zones in the Common Iliac Artery

Clinical Investigation

Percutaneous Vertebroplasty is no Risk Factor for New Vertebral Fractures and Protects Against Further Height Loss (VERTOS IV)